Recursion Pharmaceuticals is trading at $3.58 (-4.92%) as of July 10, 2026. This decline follows reports of Director Blake Borgeson selling 40,000 shares on July 7, 2026, under a Rule 10b5-1 trading plan. The insider share sales have been cited as a potential catalyst for the stock's recent volatility.